Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Iaso Biotechnology Co. Ltd. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently faces 1 pending office action. This single action is assigned to a distinct examiner and a matching number of distinct art units, indicating a highly concentrated prosecution environment. This concentration suggests that the company's current legal challenges are confined to a specific technical niche.
METCALF, MATTHEW CURRAN is identified as the busiest examiner for this portfolio. This examiner is responsible for a portion of the active workload. Because the busiest examiner's workload matches the total count of active actions, this individual handles the entirety of the company's current patent challenges. This alignment means that the company's immediate success at the patent office depends entirely on the outcome of this review.
The presence of 1 distinct art unit suggests a narrow technological focus within the Biotechnology & Pharmaceuticals sector. Practitioners should prepare for a consistent examination style, as all current feedback originates from a single source. This streamlined structure allows the company to focus its resources on a single point of contact rather than managing multiple disparate prosecution tracks. Resolving the issues raised by METCALF, MATTHEW CURRAN is the primary path forward.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| METCALF, MATTHEW CURRAN | 1 | 37.5% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550338 | UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL AND APPLICATION THEREOF | METCALF, MATTHEW CURRAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550338 | UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL AND APPLICATION THEREOF | METCALF, MATTHEW CURRAN | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550338 | UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL AND APPLICATION THEREOF | METCALF, MATTHEW CURRAN | 1647 | §102§103§112 | Final Rejection | — | Pending | Sep 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Iaso Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Matthew Curran Metcalf has the most, with 1 of Shanghai Iaso Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.